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Abstract
Introduction Receptor tyrosine kinases have been extensively
studied owing to their frequently abnormal activation in the
development and progression of human cancers. Platelet-
derived growth factor receptors (PDGFRs) are receptors with
intrinsic tyrosine kinase activity that regulate several functions in
normal cells and are widely expressed in a variety of
malignancies. After the demonstration that gastrointestinal
stromal tumours without c-Kit mutations harbour PDGFR-α -
activating mutations and that PDGFR-α  is also a therapeutic
target for imatinib mesylate, the interest for this receptor has
increased considerably. Because breast cancer is one of the
most frequent neoplasias in women worldwide, and only one
study has reported PDGFR-α  expression in breast carcinomas,
the aim of this work was to investigate the potential significance
of PDGFR-α  expression in invasive mammary carcinomas.
Methods We used immunohistochemistry to detect PDGFR-α
overexpression on a series of 181 formalin-fixed paraffin-
embedded invasive ductal breast carcinomas and in two breast
cancer cell lines: MCF-7 and HS578T. We associated its
expression with known prognostic factors and we also
performed polymerase chain reaction–single-stranded
conformational polymorphism and direct sequencing to screen
for PDGFR-α  mutations.
Results PDGFR-α  expression was observed in 39.2% of the
breast carcinomas and showed an association with lymph node
metastasis (P = 0.0079), HER-2 expression (P = 0.0265) and
Bcl2 expression (P = 0.0121). A correlation was also found with
the expression of platelet-derived growth factor A (PDGF-A; P
= 0.0194). The two cell lines tested did not express PDGFR-α .
Screening for mutations revealed alterations in the PDGFR-α
gene at the following locations: 2500A→ G, 2529T→ A and
2472C→ T in exon 18 and 1701G→ A in exon 12. We also
found an intronic insertion IVS17-50insA at exon 18 in all
sequenced cases. None of these genetic alterations was
correlated with PDGFR-α  expression. The cell lines did not
reveal any alterations in the PDGFR-α  gene sequence.
Conclusion PDGFR-α  is expressed in invasive breast
carcinomas and is associated with biological aggressiveness.
The genetic alterations described were not correlated with
protein expression, but other mechanisms such as gene
amplification or constitutive activation of a signalling pathway
inducing this receptor could still sustain PDGFR-α  as a potential
therapeutic target.
Introduction
Uncontrolled tumour cell proliferation due to abnormal activa-
tion of several growth factors and their receptors is relevant in
the events underlying human cancer development, because
the tyrosine kinases receptors form one of the most important
classes of growth factor receptors implicated in that process.
Platelet-derived growth factor receptors (PDGFRs) α  and β
are characterized by an intracellular tyrosine kinase domain
whose activation depends on ligand binding. The platelet-
derived growth factor (PDGF) family of growth factors con-
sists of five different disulphide-linked dimers, PDGF-AA, -BB,
-AB, -CC and -DD that act via the two receptors PDGFR-α
and PDGFR-β . All PDGF isoforms except PDGF-DD induce
PDGFR-α  dimerization, although this receptor binds to PDGF-
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AA with higher affinity, whereas PDGF-BB and PDGF-DD acti-
vate PDGFR-β  dimers. After receptor activation, several intra-
cellular pathways are stimulated, leading to cell proliferation
and several other crucial processes [1]. PDGFR signalling has
important functions during embryogenesis, and its overexpres-
sion is associated with several pathological conditions such as
fibrotic and vasculoproliferative diseases and cancer [2-5].
Recently, the finding that gastrointestinal stromal tumours
(GISTs) lacking c-Kit mutations harbour intragenic activating
mutations in PDGFR-α  [6,7], and that ligand-independent
constitutive activation can be blocked by means of a tyrosine
kinase inhibitor (imatinib mesylate), has increased the interest
for PDGFR-α  as a target for therapy.
The gene encoding PDGFR-α  is located at chromosome
4q11-12, which spans 23 exons and encodes a transmem-
brane protein composed of five immunoglobulin-like domains
in the extracellular region, a transmembrane domain, an ATP
binding site and a hydrophilic kinase insert domain in the intra-
cellular portion [8].
Despite increased public awareness, screening programmes
and early detection, breast cancer remains the second leading
cause of cancer death in women. This leads to a constant
search for new biological markers that could be used as prog-
nostic/predictive factors and therapeutic targets, resulting in
better disease-free survival and overall survival [9]. Given the
success of imatinib mesylate therapy of chronic myeloid leu-
kaemia and GIST, the molecular targets for this drug have
been explored in distinct types of cancer.
To the best of our knowledge, there have been few studies on
PDGFRs in mammary neoplasias and no reports on the pres-
ence of PDGFR-α  mutations in breast carcinomas. The aims
of the present study were the following: first, to evaluate the
immunohistochemistry expression of PDGFR-α  and PDGF-A
in a series of invasive ductal breast carcinomas; second, to
correlate the PDGFR-α  expression with prognostic factors in
breast cancer; and third, to screen for PDGFR-α  gene-activat-
ing mutations in breast cancer.
Materials and methods
Tissue specimens
One hundred and eighty-one formalin-fixed paraffin-embedded
cases of invasive ductal breast carcinomas were retrieved
from the histopathology files of IPATIMUP and São João Hos-
pital (Porto, Portugal). All cases were independently reviewed
on haematoxylin/eosin-stained sections by two pathologists
(FS and FM). All relevant data were available for analysis,
including age, tumour size, histological grade, axillary lymph
node status, oestrogen receptor status, p53, MIB-1 and HER-
2 expression, angiogenic index and patient survival.
The mean age of the patients was 55 years old (range 24 to
83) and the size of the tumours ranged from 2.0 to 150.0 mm
(mean 30.9).
Cell lines
MCF-7 and HS578T breast cancer cell lines (ATCC, Tedding-
ton, UK) were maintained in Eagle's minimum essential
medium and Dulbecco's modified Eagle's medium, respec-
tively, and were supplemented with 10% heat-inactivated fetal
bovine serum, 100 U/ml penicillin and streptomycin (Gibco,
Paisley, UK) in a humidified incubator at 37°C with a 5% CO2
atmosphere.
The medium was replaced every 2 to 3 days in all cell cultures.
Cell lines were grown until confluence; they were then
scraped and the suspension was transferred into a tube for
cell block preparation. After centrifugation at 1,800 r.p.m. for
5 min, the supernatants were carefully removed without dis-
lodging the cell button. After the addition of 10 ml of 10% neu-
tral buffered formalin to the intact cell button, the mixture was
kept at room temperature (18 to 25°C) for 20 min. An addi-
tional centrifugation at 1,800 rpm for 5 min was followed by
removal of the formalin supernatant and the addition of two or
three drops of bovine albumin (22% from Ortho Diagnostics).
After mixing, 10 ml of 95% ethanol was added to the sample,
which was mixed again. After a final centrifugation step, the
mixture rested for 15 min. The button was carefully loosened
to allow it to be slipped intact out of the tube, and the solution
was poured through lens paper to filter it. The cell button was
wrapped in tissue paper and placed in a tissue cassette, which
was kept in 10% neutral buffered formalin until further
processing and paraffin embedding.
Immunohistochemistry
Automated immunohistochemistry (Lab Vision Autostainer LV-
1; Lab Vision Corporation, Fremont, CA, USA) was performed
with the streptavidin–biotin–peroxidase technique, using anti-
bodies raised against human PDGFR-α  (1:200 dilution; Lab
Vision Corporation) and PDGF-A (clone N-30; 1:80 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA, USA). In brief,
antigen retrieval was performed in 10 mM citrate buffer (pH
6.0) for 20 min with wet heat (hot bath) at 98°C for PDGFR-α
or, for PDGF-A, samples were pretreated in 10 mM citrate
buffer for 15 min (3 x 5 min) in a microwave at 600 W. After
cooling to room temperature, the sections were rinsed with
PBS, which was used for all subsequent washing steps.
Endogenous peroxidase activity was blocked by the incuba-
tion of slides in 3% hydrogen peroxide in methanol for 10 min,
and non-specific epitopes were eliminated by incubation with
a blocking solution (UltraVision Block; Lab Vision Corporation)
for 10 min. The slides were incubated with the primary anti-
bodies for 30 min. After the slides had been rinsed, they were
incubated with biotinylated secondary antibody followed by
enzyme-labelled streptavidin for 10 min (UltraVision detectionAvailable online http://breast-cancer-research.com/content/7/5/R788
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system, anti-polyvalent horseradish peroxidase/diaminobenzi-
dine; Lab Vision Corporation). The immunoreaction was devel-
oped with diaminobenzidine (LabVision Corporation). Slides
were counterstained with Gill's haematoxylin.
A positive control was included in each slide run. Sections of
vessels in the corion (lamina propria) of gastrointestinal
mucosa biopsies were used as positive controls, and blood
vessels present in the periphery of the carcinomas studied
were used as internal positive controls. The cases were con-
sidered positive whenever there was cytoplasmic staining for
PDGFR-α  and PDGF-A.
Statistical analysis
Invasive ductal breast carcinomas were subclassified into
cases with or without PDGFR-α  and PDGF-A expression.
Contingency tables and the χ 2 test were used in StatView 5.0
software (SAS Institute Inc., Cary, NC, USA) to estimate the
correlation between PDGFR-α  immunoreactivity and clinical-
pathological and molecular markers previously studied for
these cases. A correlation was considered significant when-
ever P < 0.05.
Mutation analysis
Screening for mutations by polymerase chain reaction–single-
stranded conformational polymorphism (PCR-SSCP) followed
by direct DNA sequencing was performed in only 13 cases
from our series (because of the unavailability of biological
material necessary for this study), and in the two cell lines.
DNA extraction
The tumour tissue was microdissected with a sterile scalpel
under a stereomicroscope to avoid contamination with non-
neoplastic tissues. DNA extraction was performed with the
NucleoSpin kit (Macherey-Nagel, Düren, Germany) for blocks
embedded in paraffin wax.
For the human cell lines MCF-7 and HS578T, DNA was
extracted with the salting-out procedure, with some modifica-
tions. In brief, cell pellets were dissolved in SE buffer (1.2 M
sorbitol, 0.1 M EDTA, pH 8.0) and digested overnight with
proteinase K. After incubation, saturated NaCl and chloroform
were added to allow the separation of proteins from DNA.
DNA precipitation was performed with propan-2-ol. Finally,
DNA was washed with 70% ethanol and dissolved in TE buffer
(10 mM Tris/Cl, 1 mM EDTA, pH 8.0). The concentrations
were determined by spectrophotometry and aliquoted DNA
was stored at -20°C until use.
PCR-SSCP
Pre-screening of exons 12 and 18 of the PDGFR-α  gene was
performed with the primers with sequences shown in Table 1
and described elsewhere [6]. PCR was performed with 2 to 4
µl of DNA solution, PCR buffer (16 mM (NH4)2SO4, 67 mM
Tris-HCl pH 8.8, 0.01% Tween-20; Bioron GmbH, Ludwig-
shafen, Germany), 1.5 to 2.5 mM of MgCl2 (Bioron GmbH),
each dNTP (Fermentas, Ontario, Canada) at 0.2 mM, each
primer at 0.2 µM, and 1 U/µl SuperHot Taq DNA polymerase
(Bioron GmbH) in a final volume of 25 µl. Thirty-seven cycles
of denaturation (95°C), annealing (58 to 60°C) and extension
(72°C), for 45 s each, were performed in a gradient thermocy-
cler (Bio-Rad, Hercules, CA, USA).
A total of 20 µl of the PCR products was mixed with an equiv-
alent volume of denaturing loading buffer (98% formamide,
0.05% xylenecyanol and bromophenol blue). The samples
were denatured at 95°C for 10 min, put into ice and run at 4°C
in a 0.8 × MDE gel for exon 12 and in a 0.8 × MDE gel with
3% glycerol for exon 18 at 200 to 280 V, for 16 to 20 hours.
Gels were fixed in 10% ethanol for 10 min and oxidized in 1%
nitric acid solution. After 3 min, gels were stained in the dark
with a 0.012 M silver nitrate for 20 min. The gels showed an
appropriate colour in 0.28 M anydrous sodium carbonate and
0.019% formalin. The reaction was stopped by incubation in
10% acetic acid for 2 min. Subsequently, gels were dried at
80°C for 2 hours (Thermo Savant SGD5040 Slab Gel Dryer).
Direct sequencing
The abnormal PCR products for each exon screened by SSCP
were purified (MicrospinTM S-400 HR columns; Amersham
Biosciences, Little Chalfont, Bucks., UK) and analysed by
direct sequencing (Sequence Laboratories Göttingen GmbH,
Göttingen, Germany). For cell lines, after being purified, the
PCR products were subjected to a cycle sequencing reaction
with an ABI PRISM BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, CA,
USA), and then analysed with an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems) in accordance with the manu-
facturer's instructions.
Table 1
Primer sequence, annealing temperatures and fragment length, for PDGFR-α  exons
Exon Primer sequence (5'→ 3') Annealing temperature (°C) Fragment length (base pairs)
12 F, TCCAGTCACTGTGCTGCTTC; R, GCAAGGGAAAAGGGAGTCTT 58 260
18 F, ACCATGGATCAGCCAGTCTT; R, TGAAGGAGGATGAGCCTGACC 60 251
F, forward primer; PDGFR-α , platelet-derived growth factor receptor α ; R, reverse primer.Breast Cancer Research    Vol 7 No 5    Carvalho et al.
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Results
Immunohistochemistry for PDGFR-α  was performed in 181
invasive ductal breast carcinomas and in the two breast can-
cer cell lines. PDGF-A immunostaining was performed in only
48 cases because of the unavailability of biological material.
PDGFR-α  cytoplasmic expression (Fig. 1) was found in 71 of
181 cases (39.2%), and PDGF-A expression (Fig. 2) was
found in 27 of 48 cases (56.25%) (Table 2). Co-expression of
PDGFR-α  and PDGF-A was found in 10 cases and a signifi-
cant correlation was observed between the expression of the
receptor and the ligand (P = 0.0194). A positive correlation
was also found between PDGFR-α  expression and axillary
lymph node status (P  = 0.0079), Bcl2 expression (P  =
0.0121) and HER-2 expression (P = 0.0265) (Table 3). Both
cell lines showed an absence of PDGFR-α  expression, but
MCF-7 showed a low expression of PDGF-A, whereas
HS578T did not express it at all.
Five of the six cases sequenced for exon 12 did not show any
nucleotide sequence alteration and were considered normal.
PCR-SSCP followed by direct sequencing of exons 12 and 18
of PDGFR-α  revealed some alterations (Fig. 3): 2500A→ G
and 2529T→ A in exon 18 (in the same case) and a further two
in distinct cases: 2472C→ T (exon 18) and 1701G→ A (exon
12). The intronic insertion IVS17-50insA in exon 18 was found
in all cases sequenced, although four cases were hetero-
zygous and the other two homozygous for the inserted A
(Table 4). The two cell lines studied also presented the
homozygous intronic insertion IVS17-50insA, but no other
DNA sequence alterations were found among them.
The expression of PDGFR-α  varied between the cases with
the alterations described above and did not show any correla-
tion with the nucleotide alterations found.
Discussion
PDGFR is a growth factor receptor with intrinsic tyrosine
kinase activity and is deregulated in several human diseases.
Breast carcinomas are known to express PDGF; however,
there have been few studies on PDGF receptors in breast neo-
plasias, most of them related to the β  subunit [10].
In our study, 71 (39.2%) of the 181 invasive carcinomas ana-
lysed expressed PDGFR-α . Slightly different results were
obtained by Leu and colleagues [11]: using a high-density tis-
sue microarray (TMA), they analysed PDGFRs expression in
several human malignancies and found PDGFR-α  expression
in 98% of the 49 breast carcinomas studied. This high positiv-
ity could be justified by the use of a different antibody or by a
distinct evaluation, although there is no description of the
methodology used in that study. In the same study, Leu and
colleagues [11] demonstrated PDGFR-α  overexpression in
other types of carcinoma, such as ovary, prostate, colon and
lung. A high level of expression was also observed in ovarian
carcinomas (81%) in comparison with the study by Matei and
colleagues [12], which obtained 68.3% of PDGFR-α  expres-
Table 2
PDGFR-α  and PDGF-A expression in invasive ductal breast 
carcinomas
Expression PDGFR-α , n (%) PDGF-A, n (%)
Negative 110 (60.8) 21 (43.75)
Positive 71 (39.2) 27 (56.25)
Total 181 (100) 48 (100)
PDGFR-α , platelet-derived growth factor receptor α ; PDGF-A, 
platelet-derived growth factor A.
Figure 1
PDGFR-α  expression in invasive breast carcinomas by immunohisto- chemistry (streptavidin-biotin-peroxidase) PDGFR-α  expression in invasive breast carcinomas by immunohisto-
chemistry (streptavidin-biotin-peroxidase). (a) Platelet-derived growth 
factor receptor α  (PDGFR-α ) expression in pericytes and smooth mus-
cle cells of a blood vessel: internal control (original magnification × 
200); (b) Absence of PDGFR-α  expression in neoplastic cells (original 
magnification × 200); (c) PDGFR-α  diffuse cytoplasmic expression in 
neoplastic cells (original magnification × 200; inset × 400); (d) Neo-
plastic cells showing strong and diffuse cytoplasmic PDGFR-α  expres-
sion (original magnification × 400).
Figure 2
PDGF-A expression pattern studied by immunohistochemistry in inva- sive breast carcinomas PDGF-A expression pattern studied by immunohistochemistry in inva-
sive breast carcinomas. (a) Carcinoma without platelet-derived growth 
factor A (PDGF-A) expression (original magnification × 400); (b) Carci-
noma with strong PDGF-A expression (original magnification × 200; 
inset × 400).Available online http://breast-cancer-research.com/content/7/5/R788
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sion. These data suggest that the study of Leu and colleagues
[11] overestimated values of PDGFR-α  expression in different
tumour types.
Because the deregulation of PDGFR signalling can lead to an
autocrine or a paracrine stimulation of the tumour cells, we
also evaluated the expression of PDGF-A, which is the major
ligand of this receptor.
Twenty-seven (56.25%) of 48 carcinomas analysed showed
expression of PDGF-A, and we found a statistically significant
correlation with PDGFR-α , suggesting a mechanism of auto-
crine stimulation. This autocrine expression might have a
causal role in the development of a variety of human cancers
and, for example, seems to be involved in the development of
high-grade sarcomas and gliomas [13,14]. De Jong and col-
leagues [15] reported co-expression of PDGF-A/PDGFR-α  in
epithelium, stroma and endothelium of invasive breast carcino-
mas and obtained indications about possible autocrine and
paracrine mechanisms in the stroma, where they might be
responsible for a baseline stromal proliferation, and in the
endothelium, where they promote a basic level of angiogen-
Table 3
Correlation between PDGFR-α  expression, PDGF-A expression and clinical–pathological parameters in invasive ductal carcinomas
Parameter PDGFR-α  negative PDGFR-α  positive P
PDGF-A
Negative 19 (52.7%) 2 (16.7%)
Positive 17 (47.3%) 10 (83.3%) 0.0290
Age (n) 56.315 ± 11.913 (108) 52.986 ± 12.811 (70) NS (0.0788)
Tumour size, mm (n) 31.406 ± 22.056 (106) 30.101 ± 22.655 (69) NS (0.7057)
Histological grade
I 20 (19.4%) 9 (12.8%)
II 38 (36.9%) 34 (48.6%)
III 45 (43.7%) 27 (38.6%) NS (0.2595)
Axillary lymph node status
Negative 47 (48%) 18 (27.3%)
Positive 51 (52%) 48 (72.7%) 0.0079
Oestrogen receptor status
Negative 30 (27.8%) 19 (26.7%)
Positive 78 (72.2%) 52 (73.3%) NS (0.8813)
p53
Negative 38 (54.3%) 21 (53.8%)
Positive 32 (45.7%) 18 (46.2%) NS (0.9648)
MIB-1 (n) 19.449 ± 17.484 (49) 12.333 ± 12.584 (15) NS (0.1491)
HER-2
Negative (0/1+) 54 (57.4%) 26 (40%)
2+ 17 (18.1%) 10 (15.4%)
3+ 23 (24.5%) 29 (44.6%) 0.0265
Bcl2
Negative 29 (59.2%) 15 (33.3%)
Positive 20 (40.8%) 30 (66.7%) 0.0121
Angiogenesis index (n) 43.393 ± 26.498 (55) 43.633 ± 27.635 (18) NS (0.9737)
Patient survival, months (n) 24.917 ± 19.500 (48) 21.067 ± 20.405 (15) NS (0.5115)
NS, not statistically significant; PDGFR-α , platelet-derived growth factor receptor α ;
PDGF-A, platelet-derived growth factor A.Breast Cancer Research    Vol 7 No 5    Carvalho et al.
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esis. The simple presence of ligand/receptor combinations
does not necessarily indicate this type of mechanism, espe-
cially when the ligand and the receptor are produced in spatial
sites distant from each other [15]. In this context, an elegant
way to demonstrate the PDGFR-α  activation is to assay phos-
phorylated PDGFR-α  (p-PDGFR-α ) by immunohistochemistry.
However, until now p-PDGFR-α  antibodies have been reliable
only in frozen samples that were not available in our series.
To investigate the role of PDGFR-α  in neoplastic proliferation
and progression, we correlated PDGFR-α  immunoexpression
with prognostic factors and molecular markers previously
studied in this series. We did not obtain significant differences
related to the classic prognostic factors, such as tumour size,
histological grade and oestrogen receptor status. However,
we found an association between PDGFR-α  expression and
positive axillary lymph node status, suggesting that PDGFR-α -
positive tumours have a more aggressive phenotype.
We also obtained a correlation between PDGFR-α  expression
and Bcl2 expression. Bcl2 is an anti-apoptotic protein overex-
pressed in about 60 to 80% of breast cancers [16], and sev-
eral studies suggest that the low apoptotic response caused
by that overexpression allows the accumulation of genetic
alterations that might be important in breast cancer metastatic
potential [17,18]. In our study, 66.7% of the carcinomas
expressing PDGFR-α  present Bcl2 co-expression, and we
speculate that PDGFR-α  might be activating anti-apoptotic
routes such as the Bcl2 pathway.
The association found between PDGFR-α  expression and
HER-2 expression is quite interesting, and probably proves the
previous results about the correlation of PDGFR-α  pathway
with aggressiveness. HER-2 amplification/overexpression
occurs in 30% of human breast cancers and is associated
with biological aggressiveness and shortened disease-free
survival and overall patient survival [19,20]. Our results seem
to indicate that there is a relationship between these two
receptors: most carcinomas that expressed PDGFR-α  also
expressed HER-2, and the absence of PDGFR-α  was also
found at a higher frequency in carcinomas without HER-2
expression. PDGFR-α  and HER-2 are both tyrosine kinase
receptors and although they belong to different subfamilies
they can give rise to similar cellular/biological effects [21]. The
coexistence of these receptors might contribute to neoplastic
proliferation but might also influence tumour cell survival.
These results demonstrate that PDGFR-α  expression is corre-
lated with certain aggressiveness parameters of invasive
breast carcinomas, and corroborate other results [22,23]
showing PDGFR-α  overexpression associated with aggres-
sive characteristics in ovarian and renal cell carcinomas,
respectively.
As far as we know there have been no studies on PDGFR-α
expression in breast cancer cell lines; here we report that none
of the cell lines studied express PDGFR-α . Breast cancer cell
lines are known to secrete PDGFs, and, as Bronzert and col-
leagues [24] reported, MCF-7 shows some expression of
PDGF-A, as we demonstrated in our work. No information
about PDGF-A status in the HS578T cell line is available and
in our study it did not show any expression. Ligand production
by breast cancer cell lines might therefore have a role in medi-
Figure 3
Platelet-derived growth factor receptor α  (PDGFR-α ) sequencing results for exon 18 (forward strand) Platelet-derived growth factor receptor α  (PDGFR-α ) sequencing results for exon 18 (forward strand). (a) 2500A→ G (1834V) DNA sequence alter-
ation; (b) IVS17-50insA intronic insertion.
Table 4
Results of PDGFR-α  gene mutations screening in invasive 
breast carcinomas
PDGFR-α  gene sequence alterations Exon 12 Exon 18
Normal 12/13 7/13
1701G→ A (P567P) 1/13 -
2500A→ G (I834V) - 1/13
2529T→ A (I843N) - 1/13
2472C→ T (V824V) - 1/13
IVS17-50insA - 6/13
PDGFR-α , platelet-derived growth factor receptor α .Available online http://breast-cancer-research.com/content/7/5/R788
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ating paracrine stimulation of tumour growth, affecting other
cells in the microenvironment [15].
PDGFR-α  overexpression can occur by genetic amplification
or through activating mutations. PDGFR-α  amplification has
already been investigated in some tumour types, such as
oesophageal squamous cell carcinoma [25], pulmonary artery
intimal sarcomas (where it was demonstrated that PDGFR-α
amplification is strongly associated with the development of
this type of neoplasia) [26] and glioblastoma, occurring in 8 to
16% of cases [14]. However, PDGFR-α  amplification in
breast carcinomas was detected only by Daigo and col-
leagues [27], with controversial results: by array-comparative
genomic hybridization, 21% of the cases presented gene
amplification, and by metaphase-comparative genomic hybrid-
ization no amplification was detected.
As regards PDGFR-α  genetic alterations, most studies have
been performed in GIST, demonstrating that activating muta-
tions in exons 12 and 18 has a major role in the development
of these type of tumours [6,7]. It has also been shown that this
receptor can be a therapeutic target for a recently developed
drug, imatinib mesylate.
Because PDGFR-α  amplification has shown controversial
results and does not seem to be correlated with a response to
imatinib therapy, we decided to search for the activating muta-
tions frequently observed in GISTs in our sample of breast car-
cinomas, as well as in the two breast cancer cell lines MCF-7
and HS578T.
We found some alterations in PDGFR-α  gene sequence:
2500A→ G, 2529T→ A and 2472C→ T in the tyrosine kinase
II domain, all in exon 18, and 1701G→ A in the transmembrane
domain of exon 12. However, none of these alterations corre-
sponded to those described in GISTs [5-7] or even to the
unique mutation found in breast phyllodes tumours [28]. We
still observed an intronic insertion IVS17-50insA, in all cases
sequenced for exon 18, including the two cell lines. This
insertion has already been described [28] in a breast phyl-
lodes tumour and is observed in the general population, sug-
gesting that it might be a polymorphism. In other histological
tumour types, PDGFR-α -activating mutations are unknown
[29].
Although the DNA sequence alterations found do not have any
effect on protein structure and/or function, it is necessary to
emphasize that the alterations with amino acid change that
were found in the tyrosine kinase domain could be important,
because they can affect autophosphorylation (activation) and
consequent cellular effect (signalling), allowing constitutive
activation of the receptor. The cases with gene sequence
alterations do not present clinical or anatomical-pathological
features that distinguish them from the other cases, so the
possible consequences of the alterations described should be
evaluated by functional studies. Further studies are also nec-
essary to define the role of PDGFR-α  in breast oncogenesis,
as well as the inherent molecular mechanisms of this process.
It is important to stress that PDGFR-α  and other protein tyro-
sine kinases can be activated by mechanisms different from
gene mutations, such as gene fusion and amplification,
autocrine and paracrine receptor stimulation by its ligand, loss
of phosphatase activity, cross-activation by other kinases and
promoter activation/inactivation via methylation/demethylation.
Conclusion
Our results demonstrated the presence of PDGFR-α  expres-
sion in 39.2% of invasive ductal carcinomas and that this
expression was correlated with aggressiveness parameters,
such as the presence of regional lymph node metastasis,
HER-2 expression and Bcl2 expression, and also showed an
association with PDGF-A ligand expression. Although the
PDGFR-α  mutations detected in this study were not corre-
lated with protein expression, other mechanisms, such as
gene amplification or constitutive activation of a signalling
pathway, could explain the overexpression observed in our
study and still can sustain PDGFR-α  as a potential therapeutic
target in breast cancer.
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